Summary A phase I study was designed to assess whether dose intensity of an 'accelerated' cyclophosphamide -doxorubicin -etoposide (CDE) regimen plus granulocyte colony-stimulating factor (G-CSF) could be increased further, in an outpatient setting, by escalating the dose of each single drug of the regimen. Patients with previously untreated small-cell lung cancer (SCLC) received escalating doses of cyclophosphamide (C) 1100-1300 mg m-2 intravenously (i.v.) on day 1, doxorubicin (D) 50-60 mg m-2 i.v. on day 1, etoposide (E) 110-130 mg m-2 i.v. on days 1, 2, 3 and every 14 days for at least three courses. Along with chemotherapy, G-CSF (filgastrim) 5 jug kg-1 from day 5 to day 11 was administered subcutaneously (s.c.) to all patients. Twenty-five patients were enrolled into the study. All patients at the first dose level (C 1100, D 50, E 110 x 3) completed three or more cycles at the dose and schedule planned by the protocol and no 'dose-limiting toxicity' (DLT) was seen. At the second dose level (C 1200, D 55, E 120 x 3) three out of five patients had a DLT consisting of 'granulocytopenic fever' (GCPF). Another six patients were treated at this dose level with the addition of ciprofloxacin 500 mg twice a day and only two patients had a DLT [one episode of documented oral candidiasis and one of 'fever of unknown origin' (FUO) with generalised mucositis]. Accrual of patients proceeded to the third dose level (C 1300, D 60, E 130 x 3) with the prophylactic use of ciprofloxacin. Four out of six patients experienced a DLT consisting of GCPF or documented non-bacterial infection. Accrual of patients at the third dose level was then resumed adding to ciprofloxacin anti-fungal prophylaxis (fluconazole 100 mg daily) and anti-viral prophylaxis (acyclovir 800 mg twice a day) from day 5 to 11. Out of five patients treated three experienced a DLT consisting of severe leucopenia and fever or infection. With a simultaneous dose escalation and schedule acceleration it is indeed possible to take maximum advantage of G-CSF activity and to increase CDE dose intensity by a factor 1.65 -1.80 for a maximum of 3 -4 courses. The role of antimicrobial prophylaxis in this setting deserves to be investigated further.
Combination chemotherapy is the mainstay of small-cell lung cancer (SCLC) treatment (Idhe, 1992) . Whereas an agreement has been reached as to the optimal chemotherapy duration, the importance of dose intensity is still being discussed. However, at least part of the retrospective (Klasa et al., 1991) and prospective (Arriagada et al., 1993) data available seem to indicate a possible improvement in clinical outcome with the increase of chemotherapy dose intensity. Cyclophosphamide-doxorubicin-etoposide (CDE) is accepted worldwide as one of the standard chemotherapy regimens in the treatment of SCLC. This drug combination has also been used successfully in other solid tumours (Somlo et al., 1994) and haematological malignancies including non-Hodgkin's lymphomas (Sparano et al., 1993) and myeloma (Ohrling et al., 1993) . The dose-limiting toxicity of CDE is myelosuppression, particularly neutropenia, with an incidence of febrile neutropenia varying from 53% (Trillet-Lenoir et al., 1993) to 77% (Crawford et al., 1993) . The recent availability of haemopoietic growth factors has fostered studies of CDE dose intensification in SCLC. Randomised studies have shown that both granulocyte-macrophage colony-stimulating factor (GM-CSF) (Hamm et al., 1994) and granulocyte colony-stimulating factor (G-CSF) (Trillet-Lenoir et al., 1993; Crawford et al., 1993) can reduce myelosuppression associated with standard dose CDE chemotherapy in SCLC, allowing full dose chemotherapy to be delivered on time in the majority of patients. By using G-CSF or GM-CSF prophylactically, an attempt to increase the dose intensity of CDE beyond the standard has also been made. We have shown that CDE chemotherapy can be delivered every 2 weeks instead of the usual 3 weeks. This chemotherapy 'acceleration' yields a 50% increase in the projected CDE dose intensity (Ardizzoni et al., 1993) . Preliminary results from a multicentre randomised study would indicate that 'accelerated' chemotherapy in SCLC may result in a better clinical outcome (Steward et al., 1995) . The present phase I study was designed to evaluate whether dose intensity of an accelerated CDE could be increased further by escalating the dose of each single drug of the regimen. G-CSF alone or combined with anti-microbial therapy has been used to support CDE dose escalation, the aim being to assess the maximum tolerated dose intensity and the dose-limiting toxicity (DLT) of an outpatient CDE. (1) grade IV haematological toxicity lasting more than 4 days; (2) grade IV thrombocytopenia at any duration associated with bleeding or grade IV anaemia of any duration associated with cardiac failure; (3) grade IV non-haematological toxicity (other than alopecia and vomiting); (4) granulocytopenic fever (GCPF) (granulocytes <0.5 x 09 1 -' or WBC< 1.0 x 109 1-1 with at least one episode of fever> 38.2°C); (5) clinically or microbiologically documented infection requiring anti-microbial parenteral therapy; (6) fever (>38.20C) of unknown origin (FUO), regardless of the WBC count, lasting more than 3 days and requiring antimicrobial parenteral therapy; (7) ---.
receive C 1200 mg m-2, D 55 mg m-2, E 120 mg m-2 x 3 and, at the third level, C 1300 mg m-2, D 60 mg m-2, E 130 mg m-2 x 3. All patients received G-CSF (filgastrim) at the dose of 5 ig kg -self-administered s.c. from day 5 to day 11. If GCPF or infection were found as the DLT, the protocol established that another cohort of patients at the same dose level would have been treated with the addition of anti-microbial prophylaxis from day 5 to day 11, assuming GCPF was caused by occult bacterial, fungal or viral infection (Figure 1 ). Anti-microbial prophylaxis had to consist of ciprofloxacin 500 mg twice a day, fluconazole 100 mg and acyclovir 800 mg twice a day (Table I) Patients were instructed to measure their axillary body temperature at least three times a day. In case of fever > 38.2°C they had a contact their physician as soon as possible. At the hospital, axillary temperature was taken again and a complete blood count obtained; if the temperature was > 38.2°C and the granulocytes were <500 ml -the patient was considered as having a GCPF. In this case routine cultures of blood, urine and other suspected sources were performed and empirical parenteral antibiotic treatment started. Evaluation of response was due after three cycles with CT scan of thorax and repetition of all previously positive tests. Patients with limited disease, achieving partial or complete response, received thoracic radiotherapy and only those in complete response were enrolled into a prospective multicentre randomised study of prophylactic cranial irradiation.
Response criteria and dose intensity calculation Standard WHO criteria for response and toxicity evaluation were used (Miller et al., 1981) . Dose intensity was expressed in mg m-2 day-1 and calculated according to Hryniuk and Bush (1984) . As reference standard regimen to calculate the 'relative' dose intensity (RDI) planned at each dose level, a standard dose intensity CDE (C 1000 mg m-2, D 45 mg m-2, E 100x3 mg m-2 every 21 days) was used. The reported dose intensity was the average (ARDI) of the three drugs used (C, D and E). The increase over the standard in the planned dose intensity at each dose level has been calculated as follows: No. of weeks elapsing between the first and the third course As an example, the increase in cyclophosphamide dose intensity at the first dose level is reported: The actual dose intensity was calculated at the third and at the fourth cycle. All patients were considered for actual dose intensity analysis including the patients who had to stop At the second dose level, three out of five patients had a DLT. Two had GCPF after the first or second cycle and one had GCPF with a clinically documented infection (dental abscess) after the second cycle. However, the duration of GCPF was only 1 day in all the patients and no systemic infection was documented.
According to the protocol, the enrolment of patients was resumed at the same dose level adding prophylactic antibiotics consisting of ciprofloxacin 500 mg twice a day from day 5 to 11. Six more patients were treated at this dose level and only two had a DLT. One patient had a microbiologically documented infection (oral candidiasis) after the second cycle and one patient had one episode of FUO lasting for 6 days associated with stomatitis and balanoproctitis after the third cycle. The second dose level, with the addition of prophylactic ciprofloxacin, was therefore considered feasible and patient accrual proceeded to the third dose level using ciprofloxacin in adjunct to G-CSF prophylaxis. Four out of six patients experienced a DLT. One patient had GCPF and a microbiologically documented infection (oral candidiasis) after the first cycle; another had a thoracic herpes zoster infection without GCPF after three cycles; the third developed GCPF before the second cycle; and the last patient had GCPF with generalised mucositis (stomatitis and balanoproctitis) during the second cycle. Based on the observation that, with the addition of ciprofloxacin prophylaxis, all documented infections seen in our study were non-bacterial, another cohort of patients was treated at the third dose level adding to ciprofloxacin antifungal (fluconazole 100 mg daily) and anti-viral (acyclovir 800 mg twice a day) prophylaxis from day 5 to 11. Five more patients were accrued of which three experienced a DLT. One patient had GCPF and a clinically documented infection (pneumonia) after the second cycle; he died 20 days later with leucocytosis (WBC=56.0x l01-') and multiple cerebral ischaemic lesions revealed at brain CT scan. Another patient had grade IV leucopenia lasting for 5 days along with grade IV thrombocytopenia requiring platelet transfusion and hospital admission for 6 days. The third patient with DLT had GCPF without documented infection during the third course (Table III) . Dose intensity At all dose levels the median interval between cycles was 14 days (range 14-21 days). The percentages of cycles delivered on day 15, as scheduled by the protocol, at the three dose levels were 100%, 58% and 56% respectively. No dose reduction was applied. Seventeen patients were able to complete the planned three courses. Among these, seven and one patients, respectively, were given one and two more courses (Table III) .
The median percentages of actually delivered vs planned dose intensity, calculated for all patients at the third cycle, were 96%, 85%, 82% in the three dose levels respectively. At the fourth cycle, they were 85%, 75% and 71% respectively.
Response and survival Results in terms of objective response to treatment are reported in Table II 
Discussion
Since the demonstration of the important role played by dose intensity in the treatment outcome of a number of drugsensitive tumours (Gurney et al., 1993) and the availability for clinical use of haemopoietic growth factors, phase I-II studies of chemotherapy intensification have abounded (Bronchud, 1993) . The primary objective of these studies was to assess whether haemopoietic growth factors, by ameliorating chemotherapy haematological toxicity, were able to allow chemotherapy dose intensification. Increase of dose intensity above that of standard chemotherapy can be accomplished with both dose escalation and schedule acceleration. Since the main effect of GM-and G-CSF is in accelerating neutrophil recovery, and only to a lesser extent in reducing the severity of neutrophil nadir, we first aimed at verifying the possibility of accelerating chemotherapy administration. In a study of 15 SCLC patients we were able to deliver a CDE regimen, at standard doses, combined with GM-CSF every 2 weeks as opposed to the usual 3 weeks, resulting in a 50% projected dose intensity escalation (Ardizzoni et al., 1993) . Two subsequent randomised trials confirmed that such an acceleration was not possible in the absence of the use of GM-CSF Pennella et al., 1995) . The DLT of accelerated chemotherapy is cumulative thrombocytopenia which becomes severe, requiring platelet transfusions, after the fourth cycle and often precludes the completion of treatment.
In the present study we aimed at identifying the maximum tolerated dose intensity by exploring the feasibility of dose escalating a CDE regimen repeated at 2 week intervals on an outpatient basis for at least three courses. The decision to administer a fourth course of therapy was left open and was indeed taken, with no serious adverse events, in the majority of patients who did not develop a DLT. This number of courses seems adequate in the treatment of SCLC based on the results of a recent randomised British study (Bleehen et al., 1993) .
Given the definition of DLT used in our study, the MTD turned out to be the first dose level (C 1l1O mg m-2, D 50 mg m-2, E 110 mg m-2 x 3) which corresponds to a 65% projected dose intensity increase compared with a standard every 21 days CDE. This poor level of dose escalation, even in the presence of G-CSF support, is not surprising since a number of other phase I studies, most of which used GM-CSF as a haemopoietic growth factor, came to a similar conclusion in SCLC (Paccagnella et al., 1993) , breast (Hoekman et al., 1991) , ovarian (Rusthoven et al., 1991) and urothelial cancer (Scher et al., 1992) . The lack of a significant impact of myelocytic growth factors on the depth of neutrophil nadir may account for this result.
At the second dose level three of five patients developed GCPF. However, GCPF lasted only 1 day in all patients and in no instance did it require parenteral antibiotic treatment or hospitalisation. Therefore, using less strict criteria for defining a DLT, the second dose level, corresponding to an 80% projected dose intensity increase, might also be considered feasible. This amount of dose intensity increase is probably the maximum achievable on an outpatient basis, with a strategy of combined dose escalation and schedule acceleration using haemopoietic growth factors as the only supportive treatment. Further dose intensification is hindered by the development of GCPF and infection.
The efficacy of antibiotic prophylaxis in preventing infections in patients undergoing conventional chemotherapy for solid tumours is still 'sub judice'. Previous trials of prophylactic cotrimoxazole as adjunct to chemotherapy of SCLC have shown moderate benefit in reducing the infection rate (Figueredo et al., 1985; de Jongh et al., 1983) . Quinolones have been found to be more effective than cotrimoxazole in the prevention of infectious complications in the treatment of haematological malignancies (Dekker et al., 1987) . As yet no such study is available for solid tumours.
In our study, the addition of ciprofloxacin at the second (1.4-3.4) (1.2-2.9) (2.0-2.5) (12.6-13.5) (11.5-12.5) (9. Intensffied CDE in SCLC A Ardizzoni et at 1146 dose level almost abrogated the occurrence of GCPF. The small number of patients does not allow us to draw firm conclusions on the role of quinolone prophylaxis in this setting. However, since GCPF remains the dose-limiting toxicity of dose-intensified CDE, despite the use of G-CSF, the efficacy of antibiotic prophylaxis in conjunction with haemopoietic growth factors deserves further exploration with specific trials. Given the increasing prevalence of Grampositive infection in patients receiving prophylactic quinolones (Meunier, 1990) , ciprofloxacin alone may not be the optimal antibiotic treatment and the combination of ciprofloxacin with other agents such as vancomycin, rifampicin or roxithromycin is currently advocated (Archimbaud et al., 1991) . Most patients receiving G-CSF plus ciprofloxacin at the second and third dose level developed non-bacterial infections or mucositis. Both fluconazole and acyclovir have been found to be effective in preventing, respectively, fungal and viral infections in patients undergoing intensive anti-neoplastic therapy for the treatment of haematological malignancies (Wade et al., 1984; Winston et al., 1993) . Despite the use of anti-mitotic and anti-viral prophylactic therapy, the third dose level did not appear feasible in our study owing again to the occurrence of severe leucopenia and fever. However, none of the patients developed mucositis or oral candidiasis, which, on the contrary, was frequently observed in previous patient cohorts where no anti-fungal or anti-viral prophylaxis was used. Also this observation, owing to the small sample size and to the type of study design, only permits one to hypothesise on the possible role of fluconazole and acyclovir prophylaxis in moderately dose-intensive treatments for solid tumours which would need to be addressed with more appropriate studies.
In conclusion, with a simultaneous dose escalation and schedule acceleration it is indeed possible to take maximum advantage of G-CSF activity and to increase CDE dose intensity by a factor 1.65-1.80 for a maximum of 3-4 courses. The next step is to assess the impact of such a dose intensity increase on the treatment outcome of SCLC patients. A randomised prospective study comparing standard CDE vs CDE at the MTD identified in the present study is presently ongoing in Europe. The study is also designed to address the role of antibiotic prophylaxis in this setting (Tjan-Heijnen et al).
